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Abstract
Background: Anti-cancer pharmaceuticals frequently have adverse side effects on patients such as gastrointestinal
involvement limiting their clinical applications. These effects may be controlled by nutritional interventions,
however, there are few studies that have shown any mechanistic effects. In this study, we examined effects of diet
enhanced with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on 5-fluorouracil (5-FU)-induced
intestinal impairment and immunity in mice.
Methods: C57Bl6 mice were randomized to control diet, control diet + EPA, control + DHA, control + fish oil, or diet
enchanced with DHA/EPA. After seven days of each respective diet, mice, excluding those in the sham group, were
treated with 10 mg/kg/day 5-FU for 7 days. The effects of 5-FU-induced impairment in the small intestine were
assessed using cytokine concentrations in serum and tissue, secretory immunoglobulin (Ig) A, diamine oxidase
(DAO) activity, the length of the small intestine, and the expression of apoptosis signaling genes.
Results: The EPA/DHA-enhanced diet resulted in the most beneficial, synergystic and protective effect against 5-FU
induced weight loss. Protection against inflammation, impaired intestinal function, and immunity of the small
intestine were also observed. Individually, a DHA-enriched diet demonstrated a protective effect against 5-FU
damage with longer small intestine mucosal and crypt lengths, greater DAO activity, and higher IgA concentrations,
whereas the EPA-enriched diet resulted in decreased inflammatory cytokine concentrations in both plasma and
small intestine and expression of apoptosis target genes.
Conclusions: In conclusion, a diet enhanced with EPA and DHA results in synergism protecting against the
detrimental effects of 5-FU and limiting chemotherapy induced mucosal impairment.
Keyword: Omega-3 fatty acids, 5-fluorouracil, Mucosal impairment, Small intestine
Background
The clinical application of anti-cancer drugs is limited by
the frequent occurrence of severe side effects, including
decreased immunity and patient discomfort [1–4].
Chemotherapy-induced intestinal impairment and gastro-
intestinal symptoms are often severe enough for care pro-
viders and patients to reconsider treatment options and
many times stop optimal therapies. Chemotherapy in-
duces not only morphological alternations in the gut but
also impairs gut mucosal immunity [5–7]. Approximately
40 % of patients undergoing chemotherapy, and up to
60 % of those undergoing high-dose chemotherapy, de-
velop mucositis, or severe inflammation and dysfunction
of the gastrointenstial mucosa [8, 9].
Continuous infusion of 5-fluorouracil (5-FU), a fluori-
nated pyrimidine used in chemotherapy, has been shown to
reduce gut-associated lymphoid tissue (GALT) mass and
secretory IgA levels in mice model [7]. GALT is recognized
as the center of systemic mucosal immunity. 5-FU treat-
ment changes GALT mass and increase the risk of infec-
tious complications in patients with 5-FU chemotherapy
[10]. Inomata et al. demonstrated that a single oral dose of
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5-FU induces apoptosis and cell cycle arrest in intestinal
crypts of BDF1 mice [11]. They also reported that 5-FU in-
creases apoptosis and/or cell cycle arrest through systemic
exposure, and p21 and BAX expression determines an indi-
vidual cell’s fate [12].
Nutrition is essential to maintain intestinal structure and
function. A number of nutrients exert specific biological ef-
fects on both tumor and host biology [13]. Dietary fatty
acids appear to have variable effect and protection against
cancers. The long chain n–3 poly-unsaturated fatty acids
(PUFAs) such as EPA (20:5 n–3) and DHA (22:6 n–3) that
occur in fish oil are considered protective. Whereas, n–6
PUFAs such as linoleic acid (18:2 n–6), found in sunflower
seeds and corn oil, have been associated with cancer accel-
eration/promotion in rodent models [14, 15], although
more recent literature has refuted this hypothesis given no
clinical correlations [16–18]. Reduced tumor incidence and
multiplicity in rats has been observed in those fed n–3
PUFAs [19]. Protection against carcinogenesis by n–3
PUFAs may occur mediated by several mechanism includ-
ing inhibition of inflammation [20].
In a rat model, n–3 PUFAs not only inhibited cancer
development but also protected against 5-FU induced
intestinal injury [6]. Gomez de Segura et al. reported
that in the presence of 5-FU, supplementing the diet
with DHA and protein prevented intestinal damage and
the suppression of cellular apoptosis [6]. Interestingly,
enteral formulas targeted for cancer patients include fish
oil, which contains more EPA than DHA. This may be
related to the reported anti-tumor effect of EPA. How-
ever, the differing effects of EPA and DHA on 5-FU in-
duced intestinal impairment are not understood.
This study investigates the effect of a diet enriched with
EPA- and DHA compared to the individual supplementa-
tion of fish oil, EPA, or DHA alone on 5-FU induced im-
pairments in the gastrointestinal mucosa (e.g., lesions) and
cellular immunity caused by GALT impairment. We hy-
pothesized that EPA and DHA would provide additional
synergistic protection against intestinal impairment.
Methods
Animals
All animals were treated in compliance with the Guide-
lines for Proper Conduct of Animal Experiment and Re-
lated Activities (Ministry of Education, Culture, Sports,
Science and Technology of Japan) and the protocols,
which was assigned to ARRIVE guidelines, approved by
the Animal Care and Use Committee at the Tokushima
University, Tokushima, Japan. Male C57BL/6NCrSlc
mice (average body weight; 21.6 ± 2.21 g, n = 60; SLC,
Shizuoka, Hamamatsu, Japan) aged 8 weeks were
purchased for the study. The mice were housed in an
SPF air-conditioned room at 23 ± 1 °C and 50 ± 10 %
humidity with a 12-h light/dark cycle. The animals were
given ad libitum access to their respective diets. Body
weight and food intake of each mouse qt5was measured
every other day. Each mouse was in single cage.
The mice were divided into 6 groups (n = 10 each).
The sham and control diets consisted of a 1:1 mix of En-
sure® and Ensure Hi®; Abbott Japan, Tokyo, Japan (Sham
and Cont groups, respectively). Three other groups with
the control diet were then supplemented via oral gavage
of 20 g/kg/day body weight fish oil (FO; Sigma-Aldrich
Japan, Tokyo, Japan), 2,000 mg/kg/day EPA (Wako Pure
Chemical Industries, Osaka, Japan), or 2,000 mg/kg/day
DHA (Sigma Aldrich Japan, Tokyo, Japan). A final diet
fortified with EPA and DHA was used (Prosure®; Abbot
Japan, Tokyo, Japan). The composition of the control and
enhanced diets are provided in Table 1. After 7 days of the
allocated diet, daily injections of intraperitoneal 5-FU
(10 mg/kg body weight) were administered for 7 more
days; the sham group received daily injections of 0.1 mL
saline instead. Primary experimental outcomes are sur-
vival and weight changes.
Plasma and tissue isolation
Following completion of the 5-FU injections mice were
euthanized by pentobarbital and blood was immediately
collected from the right ventricle of the heart using a
heparinized syringe and placed on ice. Plasma was sepa-
rated by centrifugation at 5,000 g for 5 min at 4 °C.
Blood samples were frozen at −80 °C. We took the small
Table 1 Main dietary compositions per 80 mL
Nutrients CONT EPA/DHA–rich
Calories, kcal 100 100
Protein, g 3.52 5.33
Protein sources Casein Na, Soy protein Casein Na, Whey protein
CHO, g 13.728 16.3
CHO sources Dextrin, Sucrose Dextrin, Sucrose
Dietary fiber, g – 0.77
Fat, g 3.52 4
EPA, mg – 352
DHA, mg – 160
Fat sources Corn oil Fish oil, MCT, rapeseed oil
n-6:n-3 ratio 4.36:1 1:3.56
water, mL, % 68.45 63.5
Vitamin E, mg 3.0 16.0
Vitamin C, mg 15.2 34
Zinc, mg 1.5 2.0
Iron, mg 0.9 –
Copper, mg 0.1 –
Manganese, mg 0.2 –
Magnesium, mg 20 33
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intestine and removed the duodenum, and took 10 cm
of upper (duodenum) side of intestine as jejunum. We
used this jejunum as a small intestine and washed for
IgA assay first, and upper 2 cm of jejunum was frozen
and stored at −80 °C for gene expression analysis. sec-
ond 2 cm of it was stored in 4 % paraformaldehyde for
tissue stain to assess the length of small intestine.
ELISA assays of IL-6 and TNF-α
Serum IL-6 and TNF-α concentrations were measured
using Mouse IL-6 and TNF-α Quantikine ELISA kits
(R&D Systems, Minneapolis, MN, USA). Briefly, the assay
diluent was added to each well of a 96-well plate, followed
by serum samples and the standard; the solutions were in-
cubated for 2 h at room temperature. After each well was
washed 5 times, the solutions were incubated with 100 μL
of mouse IL-6 or TNF-α conjugate for 2 h at room
temperature. The wells were washed 5 times again and
then incubated with the substrate solution for 30 min at
room temperature while protected from the light. Stop so-
lution (100 μL) was added to each well, and the optical
density was determined at 450 nm using a microplate
reader (Tecan Japan, Kanagawa, Japan).
Gene expression analyses
Total RNA was extracted from the small intestine using
RNeasy Plus Universal Mini Kits (QIAGEN, Valencia, CA,
USA). Total RNA (1 μg) was reverse-transcribed to cDNA
in a final volume of 20 μL using the Primescript RT Re-
agent kit (Takara, Shiga, Japan). Real-time PCR was per-
formed in a final volume of 10 μL containing 50 ng of the
cDNA template and primers using SYBR green and a Ste-
pOnePlus Real-Time PCR System per manufacturer’s pre-
set protocols (Life Technologies, Carlsbad, CA, USA). All
samples were run in triplicate and a melting curve was
done to verify sample purity. Data was analyzed per fold
change using comparative Ct (ΔΔCt).
To determine the effect on inflammatory cytokines gene
expression, we measured the expression of the IL-6 and
TNFα genes. To determine the effect on apoptosis gene
expression, we measured the expression of the BH3-
interacting domain death agonist (BID), Bcl-2-associated
death promoter (BAD), Caspase-3, Caspase-8, and
Caspase-9, Bcl-2 associated X protein (BAX) and Fas cell
surface death receptor (FAS) genes. To determine the ef-
fect on anti-apoptosis gene expression, we measured the
expression of the B-cell lymphoma 2 (BCL-2) and inhibi-
tor of apoptosis 1 (IAP-1) genes.
Apoptosis
Apoptosis was measured via terminal deoxynucleotidyl
transferase–mediated dUTP nick-end labeling (TUN+ EL)
assays. Small intestines previously washed with PBS and
fixed in 3.7 % formalin, were sectioned (5 μm). TACS® 2
TdT DAB (diaminobenzidine) Kit (Trevigen, Gaithersberg,
MD, USA) was used according to the manufacturer’s in-
structions. Briefly, intestinal tissue was washed and incu-
bated in proteinase K for 15 min at room temperature. The
reaction was quenched and then washwed with PBS. Apop-
totic cells were lableled with TdT for 5 min. Samples were
again washed and visualized using strep-HRP solution for
approximately 5 min. Samples were then counterstained
with 1 % methyl green for approximately 2 min.
Diamine oxidase activity
Diamine oxidase (DAO) activity was measured by ELISA
using mice serum from Shizen-Meneki Oyo Giken Co.
(Takamatsu, Kagawa, Japan) using a previously reported
protocol [21]. Briefly, plasma was added to a cadaverine
solution and incubated. The incubation mixture was then
mixed with a color reagent containing DA-67 and perox-
idase. After a given period, the absorption of the reaction
product was measured colorimetrically at 668 nm against
the blank solution using a spectrophotometer. The plasma
DAO activity is expressed as units/L.
IgA quantification
IgA was measured from the intestinal washings using a
Mouse IgA ELISA Quantitation Set (Bethyl Laboratories,
Inc., Montgomery, TX, USA). Briefly, the plate was
coated with goat anti-mouse IgA for 1 h, blocked with
blocking solution for 30 min, and incubated with the
standard (mouse reference serum) or washing solution
at room temperature for 1 h. Incubation with HPR-
conjugated antibody was performed for another 1 h. The
incubation solution was then mixed with 3,3′,5,5′-tetra-
methylbenzidine (TMB) substrate solution, and the ab-
sorbance was measured at 450 nm using a microplate
reader (Tecan Japan, Kanagawa, Japan).
Statistical analysis
All data are expressed as mean ± SD. Statistical signifi-
cance (P < 0.05) was determined using ANOVA followed
by the Tukey’s or Bonferroni post hoc test with Graph-
Pad Prism5 (San Diego, CA, USA).
Results
EPA-DHA rich diets minimize 5-FU related weight loss
There were no significant differences between the groups
in body weight while acclimating to their respective diets
(Fig. 1a, b). All treatment groups after 5-FU lost weight.
However, EPA-DHA-rich (−0.47 ± 0.59 g, N = 7, P < 0.001)
diets or Cont + FO (−0.83 ± 1.05 g, N = 7, P < 0.001) diets
had significantly less weight loss when compared to Cont
(−2.7 ± 0.42 g, N = 7) diet alone. Furthermore, no protec-
tion against 5-FU induced weight loss was observed in
Cont + EPA (−2.85 ± 0.41 g, N = 7, N.S. vs. Cont) or Cont
+ DHA (−3.61 ± 0.89 g, N = 7, N.S. vs. Cont) diets alone
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(Fig. 1a, b). Although mice displayed significant weight
loss, no significant change in food ingestion were ob-
served, as shown in Fig. 1c, during 5-FU injections.
EPA-DHA rich diets prevent inflammatory cytokine
activation and expression
As illustrated in Fig. 2a and b, the 5-FU injections re-
sulted in significantly higher serum concentrations of
inflammatory cytokines IL-6 and TNF-α, compared to
the sham group (P < 0.01). The EPA-DHA-rich diet
had significantly lower serum concentrations of IL-6 (105
± 45 pg/mL, N = 7, P < 0.5) and TNF-α (168 ± 61 pg/mL,
N = 7, P < 0.5) compared to Control (IL-6:181 ± 68 pg/mL
and TNF-α: 323 ± 141 pg/mL, N = 7). Interstingly, the
Cont + EPA diet resulted in significantly lower concentra-
tions of IL-6 (107 ± 37 pg/mL, N = 7, P < 0.5) but no
significance was observed in TNF-α (190 ± 114 pg/mL,
N = 7, N.S.).
Relative gene expression of IL-6, within the small in-
testine was similar to sham treated animals in both EPA-
DHA rich and Cont + EPA groups, with a 1.5-2 fold in-
crease observed in the other remaining diets. An in-
crease in TNF-α gene expression was observed in all
groups following 5-FU exposure although, EPA-DHA
rich and Cont + EPA diets had relatively lower expres-
sion levels than the other diets (Fig. 2c and d).
EPA-DHA rich diets minimially affect apoptotic genes, but
upregulate anti-apoptotic genes
As shown in Fig. 3a, all mice given 5-FU had a releative
increase in pro-apoptotic genes as expected given that
chemotherapeutic agents target cellular death. EPA-
DHA rich, Cont + FO, and Cont + EPA diets were all
equally able to reduce relative expression of the apop-
totic genes: BH3-interacting domain death agonist
(BID), Caspase-3, Caspase-8, and Caspase-9, although
minimal effects were noticed in the other apoptotic
genes.
Control and Cont + DHA fed mice had no relative
change within anti-apoptotic gene expression, Whereas,
EPA-DHA-rich, Cont + FO, and Cont + EPA diets re-
sulted in greater expression of both BCL-2 and IAP-1
genes., which is likely one of the mechanisms involved
in omega-3 induced intestinal protection.
Fig. 1 An eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) rich diet minimizes weight loss associated with 5-Fluorouracil
(5-FU). a Body weight changes observed in mice during diet introduction
and while on 5-FU. b Weight gain and loss after 7 days of 5-FU
chemotherapy. c Food intake changes in mice throughout the
study. C57BL/6 mice were fed their respective diets, as shown,
with 7 days of daily intra-peritoneal injections of 10 mg/kg body
weight 5-FU. Values are presented as mean ± SD. N= 7 per experimental
groups. *** P< 0.001 vs control (cont); +++ P< 0.001 vs control. FO,
fish oil
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TUNEL staining of the intestines resulted in similar
results (Fig. 3b). The EPA-DHA rich diet had signifi-
cantly lower TUNEL positive cells compared to
Control (7.3 ± 2 % vs. 14.9 ± 3 %, N = 7, P < 0.001),
Cont + FO (12.6 ± 3 %, N = 7, P < 0.01), and Cont + DHA
(18.4 ± 4 %, N = 7, P < 0.001). EPA-DHA rich diet resulted
in no change in TUNEL positive cells when compared to
Sham or Cont + EPA.
EPA-DHA rich diet maintained intestinal integrity and
permeability
Following 5-FU injections, gross histological sections of
the small intestine revealed inflammation and disrupted
mucosal architecture in Control, Cont + FO, Cont + EPA,
and Cont + DHA (Fig. 4a). However, EPA-DHA rich diet
fed mice exhibited intestinal mucosa similar to Sham ani-
mals suggesting preserved intestinal mucosa and integrity.
This was further quantified by intestinal mucosal villi
and crypt length (Fig. 4b, c). EPA-DHA rich diets re-
vealed significantly longer villi when compared to Con-
trol (458 ± 62 μm vs. 310 ± 89 μm, N = 7, P < 0.05,
respectively), Cont + FO (317 ± 85 μm, N = 7, P < 0.05)
or Cont + EPA (292 ± 91 μm, N = 7, P < 0.05) diets, likely
resulting in preserved intestianl function and permeabil-
ity. Interestingly, there was no significant difference
among crypt length.
5-FU treatment significantly decreased DAO activity
in all groups except for the EPA-DHA rich diet group.
Furthermore, EPA-DHA rich group maintained sig-
nificantly higher DAO activity then Control (Fig. 4d;
4.3 ± 1.1 U/L vs. 2 ± 0.8U/L, N = 7, P < 0.05, respectively).
EPA-DHA rich diets preserves intestinal immunity
Intestinal IgA concentrations were significantly lower in
the groups injected with 5-FU (Fig. 5). However, mice fed
the EPA/DHA-rich diet had significantly higher IgA con-
centrations compared to Control diet (119 ± 25 μg/mL vs.
79 ± 21 μg/mL, N = 7, P < 0.05, respectively suggesting
preserved immune function. There were no significant dif-
ferences in IgA concentrations between the Control, Cont
+ FO, Cont + EPA, or Cont + DHA.
Discussion
Mucositis, especially along the gastrointestinal tract
remains a significant problem for cancer patients
Fig. 2 An eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) rich diet limits inflammatory cytokine release and gene expression within
the small intestine following 5-Fluorouracil (5-FU). Serum concentrations of IL-6 (a) and TNF-α (b) were measured. Relative gene expression (ΔΔCt)
within the small intestine were also measured for IL-6 (c) and TNF-α (d) C57BL/6 mice were fed their respective diets and them treated with 7 days
of 10 mg/kg body weight intra-peritoneal 5-Fluorouracil or 0.1 mL/day saline (sham). Values are expressed as mean ± SD. N = 7 per experimental
groups. *P < 0.05 and ***P < 0.001. FO, Fish oil. IL-6, interleukin-6. TNF-α, tumor necrosis factor alpha
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undergoing chemotherapy. In the present study, we
demonstrated a beneficial effect of omega-3 PUFAs as
well as a synergystic effect of an EPA/DHA-rich diet on
5-FU induced impairment of small intestine function
and immunity. However, together, EPA and DHA were
able to significantly limit the cytotoxic damage observed by
5-FU.
Daily intake of an EPA/DHA-rich diet resulted in less
weight loss in the presence of 5-FU than the other diets
without a difference in food intake and caloric levels.
This is likely due to preserved intestinal function. As EPA-
DHA rich group is protected against chemotherapy in-
duced intestinal injury, they are able to easily absorb nutri-
ents and continue to metabolize and grow. Anticancer
drug-induced derangements of the intestinal barrier may
pass through the gut wall and it might induce systemic
inflammation and infection [10] as well as poor nutritional
uptake resulting in malnutrition and weight loss.
Nagayoshi et al. demonstrated that even small doses of 5-
FU caused neither diarrhea nor anorexia, and markable
cell loss in GALT effector sites [7]. GALT works as a gut
mucosal immunological barrier and as a critical tissue in
Fig. 3 Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) affect apoptosis. a Gene expression of apoptosis and anti-apoptosis genes
following 7 days of 5-fluorouracil. b Quantitative analysis of TUNEL positive cells. Values are expressed as mean ± SD. N = 7 per experimental
groups. **P< 0.01 and ***P< 0.001. BAD, BCL-2-associated death promoter; BCL-2, B-cell lymphoma 2; BAX, BCL-2-associated X protein; BID, BH3-interacting
domain death agonist; IAP-1, inhibitor of apoptosis 1
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mucosal immunity [22]. In the present study, secretory
IgA concentrations were lower in the 5-FU treated groups,
and the EPA/DHA-rich diet resulted in higher IgA con-
centrations than the other diets, suggesting a protective
and preserved effect on intestinal immunity. In this study,
we measured IgA in intestinal washing according to our
previous work [23] but could not provide the variability of
the assay in this matrix.
It will be suggested that increase of crypt cell prolifera-
tion protected mucosa (vill) and crypt length [24]. Tazuke
et al. demonstrated an increase in small intestinal crypt
cell proliferation following glutamine administration in a
rat model of chemotherapy (cisplatin)-induced mucosal
injury [25]. In the present study, dietary enrichment with
EPA and DHA provided protection against intestinal mu-
cosa and crypt damage caused by 5-FU, while fish oil and
EPA supplementation did not have the same effects. Con-
sistent with these results, DAO activity, which is an
indicator of gut inflammation and integrity, was lower in
the groups with 5-FU treatment, and, among the diet
groups, was highest in the group receiving the EPA/DHA-
rich diet. Therefore, the data suggest that DHA may play
a role in protecting the small intestine from chemothera-
peutic agents.
The combined EPA-DHA diet contained less EPA and
DHA than the diets supplemented with FO, DHA, or EPA
alone, however, the combined EPA/DHA diet resulted in
the greatest protection of the small intestine. Although
this is likely related to the synergistic effects of EPA and
DHA together there may be that another component of
the diet that may have contributed to the effect. Previous
studies have demonstrated the effect of a hyper-proteic
diet in the protection against intestinal mucosa damage
which was confirmed after 5-FU treatment [26, 27]. Fur-
thermore, we previously reported that whey-based protein
diets have also been shown to be protective [28]. The
Fig. 4 Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) effectively protected against mucosal inflammation and integrity. a Gross
histological images of the small intestine after 5-fluorouracil treatment. Bar length = 100 μm. b Mucosal villi length and (c) crypt length were also
measured. d Diamine oxidase activity (DAO) a measure of gut permeability and integrity was also assessed. Values are expressed as mean ± SD. N = 7
per experimental groups. *P < 0.05, **P < 0.01, ***P < 0.001. FO, Fish oil
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addition of amounts of specific nutrients, such as glutam-
ine and arginine, would also induce benefits for intestinal
structure and function [29, 30]. These are considered that
are important for enterocyte development and may have
protective effects against radiation damage [31].
According to a report from Gomez de Segura et al.,
the dietary proteins and DHA act complementary, and
their combined use would be acceptable. This joint ad-
ministration of both nutrients, i.e. protein and DHA, im-
prove morphologic change and apoptosis in the intestine
compared to the effects of either nutrient alone [6]. In
fact, we observed different effects of each diet on apop-
tosis, and the administration of DHA alone caused a rise
in apoptosis, confirming the pro-apoptotic effect attrib-
uted to this fatty acid [32].
The benefit of DHA supplementation could not be de-
tected with standard diet in rat with intestinal impair-
ment by 5-FU and administration of supplementary
protein is also needed to protect intestinal lesions [6].
Geske et al. suggested that DNA recovery is induced
early in p53-induced apoptosis [33]. This early apoptosis
by p53 also leads to phosphatidylserine externalization
resulting in rescue and proliferation of cells.
On the other hand, supplementation with EPA inhibits
apoptosis without additional protein content. Recently,
Granci et al. demonstrated that administration of fish oil
(mainly EPA) to mice with 5-FU may be a better alterna-
tive for increasing the efficiency of chemotherapic proto-
cols through a BAX-dependent mitochondrial pathway
[34]. As shown in our inflammatory cytokine data, EPA
administration also resulted in decreased concentrations
of IL-6 and TNF-α compared to mice consuming the
diet supplemented with DHA. These cytokines promote
apoptosis; therefore, the effect of EPA on apoptosis sig-
naling might account for the decrease in these cytokines.
Furthermore, anti-apoptotic gene expression was signifi-
cantly upregulated in all diets that had EPA suggesting
again an a possible protective mechanism.
It is well known that the inhibition of tumor growth
by EPA can be reversed by n–6 PUFA linoleic acid. This
indicates an involvement of prostaglandin or lipoxygen-
ase metabolites would induce anti-tumor action [35].
Wynter et al. reported that the anti-cachectic effect of
EPA is only seen in joint with 5-FU, and that anti-
cachectic treatment with EPA may be more beneficial
when EPA is administrated during cycles of chemother-
apy [36]. This might be expected, since EPA cannot be
expected to counteract weight loss that is related to drug
toxicity. According to our data and previous publica-
tions, EPA and fish oil act primarily on tumor suppres-
sion and inflammation related to the use of 5-FU,
whereas DHA plays a key role in the suppression of 5-
FU induced intestinal impairment by repairing DNA.
Furthermore, although our data suggests EPA and DHA
have anti-apoptotic effects, which hypothetically may
promote tumorgenesis, in vitro and in vivo studies have
not shown any detrimental effects of EPA or DHA on
chemotherapeutic agents [36–38].
Interestingly, Cont + FO diet also had a combination
of EPA and DHA at higher concentrations then the
EPA-DHA rich diet. Interestingly, Cont + FO did not re-
sult in as much protection as EPA-DHA rich diets alone.
We hypothesize that this may likely be because FO con-
tains only 10-20 % EPA and DHA and has a variety of
other fatty acids including omega-6 fatty acids which
have been shown to promote tumor cell proliferation
[39] and result in weight gain, tissue inflammation, and
inhibition of EPA and DHA protective effects when
taken in excess [40, 41].
Taken together our data suggests that a diet only rich
in EPA and DHA demonstrated a protective synergistic
effect against 5-FU induced intestinal impairment. These
findings further demonstrate that a formula rich in EPA
and DHA brings benefits to patients while undergoing
chemotherapy and has future clinical implications. How-
ever, future clinical studies investigating human effects
and changes on inflammation and intestinal impairment
induced by cancer and chemotherapy are necessary as
well as a more detailed analysis regarding the different
roles of omega-3 fatty acids such as EPA and DHA.
Conclusion
The diet enhanced with EPA and DHA results in syner-
gism protecting against the detrimental effects of 5-FU
and limiting chemotherapy induced mucosal impairment.
Fig. 5 Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
maintained intestinal immunity after 5-Fluorourcil treatment. Secretory
IgA concentrations were measured by from the small intestines. Values
are expressed as mean ± SD. N = 7 per experimental groups. *P< 0.05.
FO, Fish oil
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